Table 2.
Treatment characteristics; median values are shown in parentheses
| EBRT dose (whole pelvis) + ICBT point A dose | ||||
|---|---|---|---|---|
| 30–30.6 Gy/15–17 fr | 20.4–24 Gy/4 fr | 11 (11.3%) | ||
| 39.6–40 Gy/20–22 fr | 17.3 Gy/2 fr | 5 (5.6%) | ||
| 17.3–18 Gy/3 fr | 51 (57.3%) | |||
| 50–50.4 Gy/25–28 fr | 12–14.5 Gy/2–3 fr | 22 (27.8%) | ||
| Width of CS | ||||
| 2 cm | 1 (1.3%) | |||
| 3 cm | 11 (13.6%) | |||
| 4 cm | 67 (82.7%) | |||
| 5 cm | 2 (2.5%) | |||
| Dose of CS (Gy) | 3.6–22 (12.0) | |||
| Volume of HR-CTV (cc) at initial ICBT | 10.0–108.7 (18.2) | |||
| Total EQD2 (whole pelvic EBRT + ICBT, Gy) | ||||
| HR-CTV D90 | 50.4–109.6 (69.8) | |||
| Rectal D2cc | 48.7–142.7 (69.9) | |||
| Bladder D2cc | 52.8–121.7 (74.7) | |||
| OTT (days) | 36–83 (54) | |||
| Neoadjuvant chemotherapy | 4 (4.5%) | |||
| Concurrent chemotherapy | 62 (69.7%) | |||
| Weekly CDDP | 28 (45.2%) | |||
| 1–3 course | 14 (50.0%) | |||
| 4–6 course | 14 (50.0%) | |||
| Weekly nedaplatin | 34 (54.8%) | |||
| 1–3 course | 7 (20.6%) | |||
| 4–6 course | 27 (79.4%) | |||
| Adjuvant chemotherapy | 28 (31.4%) | |||
EBRT = External beam irradiation, ICBT = Intracavitary brachytherapy, CS = Central Shielding, HR-CTV = High risk CTV, OTT = Overall treatment time.